IONIS PHARMACEUTICALS INC (IONS)

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 927 full-time employees. The firm has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. The company has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Company Info

IONIS PHARMACEUTICALS INC

2855 Gazelle Court

Carlsbad CALIFORNIA 92010

P: 17609319200

CEO: Brett P. MONIA

Employees: 927

Website: https://www.ionispharma.com/